Colombian decree will allow 'non-comparable' biologics, say R&D firms
This article was originally published in Scrip
The publication of a Colombian decree on the evaluation of biotechnological medicines has caused something of a stir, not least because it offers three separate approval pathways, one of which R&D-based companies say will allow the approval of "non-comparable" versions of originator biologic medicines.
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.